U.K. pharma increasingly violates voluntary industry marketing codes, and probes are taking longer

Taking stock of the drug industry, from the lab to the medicine chest

June 25, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | U.K. pharma increasingly violates voluntary industry marketing codes, and probes are taking longer "We we want regulators to take a proactive and adversarial stance, actively monitoring drug company misconduct," said author Piotr Ozieranski By Ed Silverman STAT+ | Former Moderna executive launches genome editing company Tal Zaks, once a skeptic of genome editing, says Exsilio Therapeutics has a way to insert whole genes with minimal disruption to DNA. By Jason Mast STAT+ | Opinion: Could billions of dollars in AI funding lead to the same number of new drugs? Pharma R&D systems — how drugs are developed, tested, approved, and manufactured — must adapt to upcoming increase in speed and scale. By Ashu Singhal and Sajith Wickramasekara Multidisciplinary Association for Psychedelic Studies Opinion: Turning a 'no' vote into progress: How to advance MDMA-assisted psychotherapy for PTSD The silver lining in a "no" vote on a new drug application for MDMA-assisted psychotherapy: a way forward for better research. By Andrew D. Forsyth, Mallory O. Johnson, and Jae M. Sevelius

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser